ATXN2 and spinocerebellar ataxia type 2: CAG repeat amplification of the ATXN2 gene is a causative factor in SCA2 [74].Therapeutic approaches may involve strategies to target this gene mutation, such as targeting ATXN2 mRNA using antisense oligonucleotides (ASOs) to reduce the production of aberrant ATXN2 protein.